How much insulin-like growth factor I (IGF-I) circulates? Impact of standardization on IGF-I assay accuracy

被引:55
|
作者
Quarmby, V
Quan, C
Ling, V
Compton, P
Canova-Davis, E
机构
[1] Genentech Inc, Dept Bioanalyt Technol, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Biostat, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Analyt Chem, San Francisco, CA 94080 USA
来源
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 1998年 / 83卷 / 04期
关键词
D O I
10.1210/jc.83.4.1211
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is a significant systematic difference between the normal range obtained from ethylenediamine tetraacetate plasma samples using the Genentech total insulin-like growth factor I (IGF-I) RIA and normal ranges for other total IGF-I RIAs. To determine whether the quality of the assay standard was the cause of this systematic difference, we analyzed commercially available preparations of recombinant human IGF-I (rhIGF-I) typical of those used as IGF-I immunoassay standards along with our own well characterized rhIGF-I assay standard. For the commercial standards, high performance liquid chromatography-derived purities were low, and some vendor-assigned protein concentrations were inconsistent with values from quantitative amino acid analysis. The Genentech rhIGF-I assay standard was highly pure and quantitatively correct. However, the poor quality of some commercial rhIGF-I preparations was not the primary reason for the systematic discrepancy between the Genentech total IGF-I RIA normal range and most other normal ranges. Most assays for total IGF-I are calibrated against the WHO International Reference Reagent (IRR) for IGF-I Immunoassays (87/ 518). The Genentech total IGF-I RIA is not calibrated against WHO IRR 87/518. The protein content assigned to WHO IRR 87/518 was a consensus value from a multicenter collaborative study. Physicochemical analyses showed that WHO IRR 87/518 is Met(-1)-IGF-I of low purity (44%), and that the assigned protein content is higher than the value determined by quantitative amino acid analysis. Thus, assays that are calibrated against WHO IRR 87/518 will report total IGF-I concentrations in excess of actual values. We believe that calibration against WHO IRR 87/518 is the cause of the systematic discrepancy between the Genentech IGF-I assay normal range and most other normal ranges, and that much of the plasma IGF-I concentration data in the literature are of questionable accuracy.
引用
收藏
页码:1211 / 1216
页数:6
相关论文
共 50 条
  • [31] INSULIN-LIKE GROWTH FACTOR-I (IGF-I) DEPENDENT PHOSPHORYLATION OF THE IGF-I RECEPTOR IN MG-63 CELLS
    LOPACZYNSKI, W
    HARRIS, S
    NISSLEY, P
    REGULATORY PEPTIDES, 1993, 48 (1-2) : 207 - 216
  • [32] Insulin-like growth factor-I (IGF-I)/IGF-I receptor axis and increased invasion activity of fibroblasts in keloid
    Ohtsuru, T
    Yoshimoto, H
    Ishihara, H
    Namba, H
    Yamashita, S
    ENDOCRINE JOURNAL, 2000, 47 : S41 - S44
  • [33] Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells
    Li, GL
    Barrett, EJ
    Wang, H
    Chai, WD
    Liu, ZQ
    ENDOCRINOLOGY, 2005, 146 (11) : 4690 - 4696
  • [34] Quantification of insulin-like growth factor I (IGF-I) without interference by IGF binding proteins
    DeLeon, DD
    Asmerom, Y
    ENDOCRINOLOGY, 1997, 138 (05) : 2199 - 2202
  • [35] Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer
    Krajcik, RA
    Borofsky, ND
    Massardo, S
    Orentreich, N
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (12) : 1566 - 1573
  • [36] Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling
    Pandini, G
    Vigneri, R
    Costantino, A
    Frasca, F
    Ippolito, A
    Fujita-Yamaguchi, Y
    Siddle, K
    Goldfine, ID
    Belfiore, A
    CLINICAL CANCER RESEARCH, 1999, 5 (07) : 1935 - 1944
  • [37] Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers
    Mishra, L
    Bass, B
    Ooi, BS
    Sidawy, A
    Korman, L
    GROWTH HORMONE & IGF RESEARCH, 1998, 8 (06) : 473 - 479
  • [38] Insulin resistance in Laron syndrome (Primary insulin-like growth factor-I (IGF-I) deficiency) and effect of IGF-I replacement therapy
    Laron, Z
    Avitzur, Y
    Klinger, B
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 1997, 10 : 105 - 115
  • [39] Insulin-like growth factor (IGF-I) mRNA and IGF-I receptor in trout testis and in isolated spermatogenic and sertoli cells
    LeGac, F
    Loir, M
    LeBail, PY
    Ollitrault, M
    MOLECULAR REPRODUCTION AND DEVELOPMENT, 1996, 44 (01) : 23 - 35
  • [40] CHEMICAL SYNTHESIS OF HUMAN INSULIN-LIKE GROWTH FACTOR-I (IGF-I)
    FUNAKOSHI, S
    FUJII, N
    YAJIMA, H
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (11) : S229 - S229